Ginkgo Bioworks Holdings Inc. (NYSE:DNA) saw a downside of -0.69% to close Friday at $11.51 after subtracting -$0.08 on the day. The 5-day average trading volume is 7,730,680 shares of the company’s common stock. It has gained $13.74 in the past week. An average of 8,061,750 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 6,879,230.
DNA’s 1-month performance is 15.45% or $1.54 on its low of $8.90 reached on 09/13/21. The company’s shares have touched a 52-week low of $8.90 and high of $14.25. YTD, DNA has achieved 13.74%. However, the current price is down -19.23%% from the 52-week high price.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Ginkgo Bioworks Holdings Inc. (DNA) has a trailing price-to-earnings (P/E) ratio of 33.83 for the broader industry and 32.48 for the sector, meaning that investors are optimistic about the stock’s future prospects.DNA stock has a beta of 0.00. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 170.45 while the price-to-book (PB) in the most recent quarter is 1.69.
Ginkgo Bioworks Holdings Inc.’s quick ratio for the recent quarter was 0.20, with the current ratio over the same period at 0.20 meaning that DNA stock is able to fulfill its debt obligations.
EBITDA for the quarter stood at more than -$5.31 million. DNA stock balance sheet for the recent quarter shows that total liabilities totaled 1.72 billion, with total debt at $16.36 million. Shareholders hold equity totaling $215.62 million
Let’s look briefly at Ginkgo Bioworks Holdings Inc. (DNA) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 01 October was 49.37% to suggest the stock is trending Neutral, with historical volatility in this time period at 62.25%.
The stock’s 5-day moving average is $12.29, reflecting a -8.65% or -$1.09 change from its current price. DNA is currently trading +15.39% above its 20-day SMA, +16.62% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by +15.91%.
Stochastic %K and %D was 52.39% and 62.34% and the average true range (ATR) pointed at 0.94. The RSI (14) points at 53.34%, while the 14-day stochastic is at 45.20% with the period’s ATR at 0.81. The stock’s 9-day MACD Oscillator is pointing at -0.45 and 0.01 on the 14-day charts.
In the most recent analyst report for Ginkgo Bioworks Holdings Inc. (NYSE: DNA), HSBC Securities launched coverage with a Buy rating. Analysts offering their rating for DNA stock have a consensus rating for the stock as Buy. Currently, 0 brokerage advisors rate DNA as a “sell,”, while 0 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 1 have offered a “buy” rating.
What is DNA’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $14.00 and a high of $14.00, with their median price target at $14.00. Looking at these predictions, the average price target given by analysts is for Ginkgo Bioworks Holdings Inc. (DNA) stock is $14.00.